Role of Telomeres and Telomerase in Parkinson's Disease�A New Theranostics?
Date
2023-08-21Author
Vellingiri, Balachandar
Balasubramani, Kiruthika
Iyer, Mahalaxmi
Raj, Neethu
Elangovan, Ajay
Song, Kwonwoo
Yeo, Han-Cheol
Jayakumar, Namitha
Kinoshita, Masako
Thangarasu, Ravimanickam
Narayanasamy, Arul
Dayem, Ahmed Abdal
Prajapati, Vijay Kumar
Gopalakrishnan, Abilash Valsala
Cho, Ssang-Goo
Metadata
Show full item recordAbstract
Parkinson's disease (PD) is a complex condition that is significantly influenced by oxidative stress and inflammation. It is also suggested that telomere shortening (TS) is regulated by oxidative stress which leads to various diseases including age-related neurodegenerative diseases like PD. Thus, it is anticipated that PD would result in TS of peripheral blood mononuclear cells (PBMCs). Telomeres protect the ends of eukaryotic chromosomes preserving them against fusion and destruction. The TS is a normal process because DNA polymerase is unable to replicate the linear ends of the DNA due to end replication complications and telomerase activity in various cell types counteracts this process. PD is usually observed in the aged population and progresses over time therefore, disparities among telomere length in PBMCs of PD patients are recorded and it is still a question whether it has any useful role. Here, the likelihood of telomere attrition in PD and its implications concerning microglia activation, ageing, oxidative stress, and the significance of telomerase activators are addressed. Also, the possibility of telomeres and telomerase as a diagnostic and therapeutic biomarker in PD is discussed. � 2023 Wiley-VCH GmbH.
Journal
Advanced Biology
Access Type
Open Access